Author

Qiang Wei

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Comparison of Beiyi® and its reference product Enantone® as agonists of luteinizing hormone-releasing hormone against prostate cancer: a multicenter, randomized single-dose study

Background Leuprolide acetate is a potent agonist of luteinizing hormone-releasing hormone that has been licensed to treat prostate cancer. The microsphere formulation of leuprolide acetate called Beiyi®, developed in China, has shown favorable pharmacokinetics, pharmacodynamics and safety similar to those of the refer...

Yu-Yao Yi, P. Shen, Tong-Sen Zheng et al. · Frontiers in Pharmacology · 0 citations

Review Open access Sep 2026

Advancements and future directions in transforming therapies of prostate cancer.

ABSTRACT The treatment landscape for advanced prostate cancer (PCa) has significantly evolved in recent years, marked by the introduction of several novel therapies. Targeting the androgen receptor (AR) remains a cornerstone of treatment, with drugs, such as abiraterone and next-generation antiandrogens, providing subs...

Jin-Ge Zhao, Bo Tang, Hao Zeng et al. · Chinese Medical Journal · 0 citations